167 related articles for article (PubMed ID: 24564252)
1. Can we accurately report PTEN status in advanced colorectal cancer?
Hocking C; Hardingham JE; Broadbridge V; Wrin J; Townsend AR; Tebbutt N; Cooper J; Ruszkiewicz A; Lee C; Price TJ
BMC Cancer; 2014 Feb; 14():128. PubMed ID: 24564252
[TBL] [Abstract][Full Text] [Related]
2. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
[TBL] [Abstract][Full Text] [Related]
3. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.
Price TJ; Hardingham JE; Lee CK; Townsend AR; Wrin JW; Wilson K; Weickhardt A; Simes RJ; Murone C; Tebbutt NC
Cancer Med; 2013 Jun; 2(3):277-85. PubMed ID: 23930204
[TBL] [Abstract][Full Text] [Related]
5. In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.
Picanço-Albuquerque CG; Morais CL; Carvalho FL; Peskoe SB; Hicks JL; Ludkovski O; Vidotto T; Fedor H; Humphreys E; Han M; Platz EA; De Marzo AM; Berman DM; Lotan TL; Squire JA
Virchows Arch; 2016 May; 468(5):607-17. PubMed ID: 26861919
[TBL] [Abstract][Full Text] [Related]
6. In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity.
Ágoston EI; Micsik T; Ács B; Fekete K; Hahn O; Baranyai Z; Dede K; Bodoky G; Bursics A; Kulka J; Krenács T; Győrffy B; Harsányi L; Szász AM
Diagn Pathol; 2016 Jul; 11(1):61. PubMed ID: 27392434
[TBL] [Abstract][Full Text] [Related]
7. The relationship between and clinical significance of MicroRNA-32 and phosphatase and tensin homologue expression in colorectal cancer.
Wu W; Yang P; Feng X; Wang H; Qiu Y; Tian T; He Y; Yu C; Yang J; Ye S; Zhou Y
Genes Chromosomes Cancer; 2013 Dec; 52(12):1133-40. PubMed ID: 24123284
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
Cuzick J; Yang ZH; Fisher G; Tikishvili E; Stone S; Lanchbury JS; Camacho N; Merson S; Brewer D; Cooper CS; Clark J; Berney DM; Møller H; Scardino P; Sangale Z;
Br J Cancer; 2013 Jun; 108(12):2582-9. PubMed ID: 23695019
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
Karapetis CS; Jonker D; Daneshmand M; Hanson JE; O'Callaghan CJ; Marginean C; Zalcberg JR; Simes J; Moore MJ; Tebbutt NC; Price TJ; Shapiro JD; Pavlakis N; Gibbs P; Van Hazel GA; Lee U; Haq R; Virk S; Tu D; Lorimer IA;
Clin Cancer Res; 2014 Feb; 20(3):744-53. PubMed ID: 24218517
[TBL] [Abstract][Full Text] [Related]
11. Opposite Prognostic Impact of Single PTEN-loss and
Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
Atreya CE; Sangale Z; Xu N; Matli MR; Tikishvili E; Welbourn W; Stone S; Shokat KM; Warren RS
Cancer Med; 2013 Aug; 2(4):496-506. PubMed ID: 24156022
[TBL] [Abstract][Full Text] [Related]
13. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
14. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Mao C; Wu XY; Yang ZY; Threapleton DE; Yuan JQ; Yu YY; Tang JL
Sci Rep; 2015 Feb; 5():8065. PubMed ID: 25639985
[TBL] [Abstract][Full Text] [Related]
15. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
16. A robust immunohistochemical assay for detecting PTEN expression in human tumors.
Sangale Z; Prass C; Carlson A; Tikishvili E; Degrado J; Lanchbury J; Stone S
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):173-83. PubMed ID: 20930614
[TBL] [Abstract][Full Text] [Related]
17. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.
Razis E; Briasoulis E; Vrettou E; Skarlos DV; Papamichael D; Kostopoulos I; Samantas E; Xanthakis I; Bobos M; Galanidi E; Bai M; Gikonti I; Koukouma A; Kafiri G; Papakostas P; Kalogeras KT; Kosmidis P; Fountzilas G
BMC Cancer; 2008 Aug; 8():234. PubMed ID: 18700047
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: a systematic review.
Liu J; Ke F; Chen T; Zhou Q; Weng L; Tan J; Shen W; Li L; Zhou J; Xu C; Cheng H; Zhou J
J Cancer Res Clin Oncol; 2020 Apr; 146(4):809-820. PubMed ID: 32146564
[TBL] [Abstract][Full Text] [Related]
19. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.
Morais CL; Herawi M; Toubaji A; Albadine R; Hicks J; Netto GJ; De Marzo AM; Epstein JI; Lotan TL
Prostate; 2015 Oct; 75(14):1610-9. PubMed ID: 26178158
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss in colorectal cancer.
Lin PC; Lin JK; Lin HH; Lan YT; Lin CC; Yang SH; Chen WS; Liang WY; Jiang JK; Chang SC
World J Surg Oncol; 2015 May; 13():186. PubMed ID: 25986931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
